Cardiovascular News’ top 10 most popular stories of April 2022

980

The most read stories from across Cardiovascular News in April 2022 include highlights and late-breaking data from the American College of Cardiology’s annual scientific sessions (ACC 2022, 2–4 April, Washington DC, USA), as well as evidence-based recommendations for percutaneous transaxillary arterial access and training for clinicians.

  1. Analysis finds lower rate of structural valve deterioration with TAVI than SAVR at five years
    Patients who received a transcatheter supra-annular self-expanding heart valve had less structural deterioration in the valve after five years compared with similar patients who received a biologic valve surgically.
  2. FFR-guided PCI non-inferior to IVUS for intermediate coronary stenosis
    A head-to-head comparison of fractional flow reserve (FFR) and intravascular ultrasound (IVUS) guided percutaneous coronary intervention (PCI) in patients with intermediate coronary artery stenosis found that FFR was non-inferior to IVUS for adverse clinical outcomes at a two-year follow-up.
  3. Corvia announces publication of REDUCE LAP-HF II data
    Corvia Medical announced publication of analyses from its global, phase III REDUCE LAP-HF II randomised trial of heart failure (HF) patients with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction.
  4. “Promising” one-year results for Pascal device in CLASP-TR trial
    Patients with tricuspid regurgitation (TR) who received a Pascal transcatheter valve (Edwards Lifesciences) experienced significant improvements in blood flow through the heart and in quality of life at one year.
  5. Three-year data show “durable blood pressure reductions” through renal denervation
    Long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial have been presented during a featured clinical research session at the American College of Cardiology’s annual scientific sessions (ACC 2022, 2–4 April, Washington DC, USA).
  6. FAME 3 shows FFR-guided PCI leads to a faster recovery versus surgery
    Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) leads to a faster improvement in quality of life, with similar outcomes at 12-month follow-up compared with coronary artery bypass graft (CABG) surgery.
  7. NACMI registry finds reducing rates of death among STEMI patients with COVID-19
    Latest results from the North American COVID-19 STEMI (NACMI) registry reported a 25% reduction in early mortality in 2021 compared to 2020 among patients with ST-segment elevation myocardial infarction (STEMI) and COVID-19 infection and zero deaths for patients vaccinated against SARS-CoV-2.
  8. TAVI patients treated with edoxaban see fewer incidences of leaflet thrombosis compared to DAPT
    Patients treated with edoxaban for six months after a transcatheter aortic valve implantation (TAVI) procedure experienced fewer incidences of leaflet thrombosis compared to patients receiving dual antiplatelet therapy (DAPT).
  9. First patient enrolled in BIOMICS study for CTO-PCI
    Biosensors International has announced the enrolment of the first patient in the BIOMICS study, a prospective, multicentre evaluation of the safety and effectiveness of the Biosensors Microcatheter in patients undergoing percutaneous coronary intervention (PCI) for the treatment of chronic total occlusions (CTO).
  10. SCAI issues position paper on transaxillary arterial access
    The Society for Cardiovascular Angiography & Interventions (SCAI) has released an official position statement providing evidence-based recommendations for percutaneous transaxillary arterial access and training for clinicians.

LEAVE A REPLY

Please enter your comment!
Please enter your name here